Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15460097 | 0.94 | ALOX15 (0.36) | CNR2P2RX7ALOX15CNR1 | |
| SCHEMBL10065662 | 0.94 | CNR2 (0.34) | CNR2CYP1A2CYP2C19RAB9ACYP2D6 | |
| SCHEMBL10071820 | 0.91 | EPHX2 (0.33) | CNR2P2RX7 | |
| SCHEMBL10065730 | 0.90 | CNR2 (0.35) | CNR2CYP1A2CYP2C19RAB9ACYP2D6 | |
| SCHEMBL16270497 | 0.90 | ANO1 (0.32) | CNR2CYP2C19CYP2D6P2RX7CYP2C9 | |
| SCHEMBL2809026 | 0.89 | CNR2 (0.37) | CNR2CYP1A2CYP2C19RAB9ACYP2D6 | |
| SCHEMBL2805120 | 0.88 | CNR2 (0.38) | CNR2CYP1A2CYP2C19RAB9ACYP2D6 | |
| SCHEMBL2811468 | 0.88 | CNR2 (0.37) | CNR2CYP1A2CYP2C19RAB9ACYP2D6 | |
| SCHEMBL185858 | 0.88 | CNR2 (0.37) | CNR2CYP1A2CYP2C19RAB9ACYP2D6 | |
| SCHEMBL15460053 | 0.88 | OPRL1 (0.34) | CNR2P2RX7ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606043-B1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| WO-2012022794-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HRH2 | CNR2 76/4885CYP1A2 508/4885CYP2C19 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.